PIK3CA and breast carcinoma: Crowder et al. examined relationships between pharmacologic inhibition and somatic mutations in PI3K catalytic subunits in HR+ breast cancer using RNA interference and PI3K catalytic subunit inhibitor BEZ235 [6].